Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing

• Main Authors: S. Zielen, P. Kuna, W. Aberer, S. Lassmann, O. Pfaar, L. Klimek, A. Wade, K. Kluehr, J. Raab, D. Wessiepe, D. Lee, M.F. Kramer, K. Gunawardena, T. Higenbottam, M.D. Heath, M.A. Skinner, P.J. de Kam
• Format: Article
• Language: English
• Published: Elsevier 2019-11-01
• Series: World Allergy Organization Journal
• Online Access: http://www.sciencedirect.com/science/article/pii/S1939455119312311

Background: Pollinex Quattro Grass (PQ Grass) is an effective, well-tolerated, short pre-seasonal subcutaneous immunotherapy to treat seasonal allergic rhinoconjunctivitis (SAR) due to grass pollen. In this Phase II study, 4 cumulative doses of PQ Grass and placebo were evaluated to determine its optimal cumulative dose. Methods: Patients with grass pollen-induced SAR were randomised to either a cumulative dose of PQ Grass (5100, 14400, 27600 and 35600 SU) or placebo, administered as 6 weekly subcutaneous injections over 31–41 days (EudraCT number 2017-000333-31). Standardized conjunctival provocation tests (CPT) using grass pollen allergen extract were performed at screening, baseline and post-treatment to determine the total symptom score (TSS) assessed approximately 4 weeks after dosing. Three models were pre-defined (Emax, logistic, and linear in log-dose model) to evaluate a dose response relationship. Results: In total, 95.5% of the 447 randomized patients received all 6 injections. A highly statistically significant (p < 0.0001), monotonic dose response was observed for all three pre-specified models. All treatment groups showed a statistically significant decrease from baseline in TSS compared to placebo, with the largest decrease observed after 27600 SU (p < 0.0001). The full course of 6 injections was completed by 95.5% of patients. Treatment-emergent adverse events were similar across PQ Grass groups, and mostly mild and transient in nature. Conclusions: PQ Grass demonstrated a strong curvilinear dose response in TSS following CPT without compromising its safety profile. Keywords: Allergen immunotherapy, Allergoid, Cumulative dose, Curvilinear dose response, Grass pollen